<SEC-DOCUMENT>0001193125-23-091830.txt : 20230804
<SEC-HEADER>0001193125-23-091830.hdr.sgml : 20230804
<ACCEPTANCE-DATETIME>20230405111957
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-23-091830
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230405

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anika Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730
		BUSINESS PHONE:		(781) 457-9000

	MAIL ADDRESS:	
		STREET 1:		32 WIGGINS AVENUE
		CITY:			BEDFORD
		STATE:			MA
		ZIP:			01730

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA THERAPEUTICS INC
		DATE OF NAME CHANGE:	19970114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g480900dsp01.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Northern Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02210</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 617 570 1000</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">April&nbsp;5, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr.&nbsp;Daniel Duchovny </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Office of Mergers and Acquisitions
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Division of Corporation Finance </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange
Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 F Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Washington, D.C. 20549 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left"><B>Re:</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>&nbsp;&nbsp;Anika Therapeutics, Inc. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>Preliminary Proxy Statement filed on March&nbsp;27, 2023</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B>File <FONT STYLE="white-space:nowrap">No.&nbsp;001-14027</FONT></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Mr.&nbsp;Duchovny: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">This letter is being
submitted on behalf of our client, Anika Therapeutics, Inc. (the &#147;<B>Company</B>&#148;), in response to comments contained in the letter dated April&nbsp;4, 2023 from Daniel Duchovny, Special Counsel, Office of Mergers and Acquisitions of the
Staff (the &#147;<B>Staff</B>&#148;) of the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) with respect to the Company&#146;s Preliminary Proxy Statement on Schedule 14A that was filed on March&nbsp;27, 2023 (the
&#147;<B>Preliminary</B><B></B><B>&nbsp;Proxy Statement</B>&#148;). The Company is concurrently filing Amendment No.&nbsp;1 to the Preliminary<B></B>&nbsp;Proxy Statement (&#147;<B>Amendment No.</B><B></B><B>&nbsp;1</B>&#148;), which includes
changes in response to the Staff&#146;s comments. For your convenience, we are also delivering to you by email a marked copy of Amendment No.&nbsp;1, showing the Company&#146;s changes to the Preliminary Proxy Statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">For reference purposes, the Staff&#146;s numbered comments have been reproduced in italics herein with responses immediately following such
comment. Page references in the responses refer to the pages in Amendment No.&nbsp;1. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Preliminary Proxy Statement </U></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Proposal 1: Election of Directors, page 11 </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>We note the following disclosure on page 11 and in the form of proxy card that if &#147;you vote
&#147;FOR&#148; more than two (2)&nbsp;nominees on your WHITE proxy card, your shares will be voted &#147;FOR&#148; each of the Board recommended nominees and &#147;WITHHOLD&#148; on the Caligan nominees.&#148; Please provide a detailed legal
analysis supporting the validity of this approach both under the federal proxy rules, in particular Rule <FONT STYLE="white-space:nowrap">14a-4(e),</FONT> and under applicable state law. Alternatively, please amend the disclosure here (and similar
disclosure elsewhere, including on the proxy card) to provide that an overvote on Proposal 1 will result in the votes on that proposal being invalid and not counted. </I></P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr. Daniel Duchovny </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April 5, 2023 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Response to Comment No.</U><U></U><U>&nbsp;1</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company acknowledges the Staff&#146;s comment and advises the Staff that it has revised the Proxy Statement at pages 12 and 84 to indicate
that an overvote on Proposal 1 will result in the votes on that proposal being invalid and not counted. The Company has also made corresponding changes to the proxy card. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Annex A, page <FONT STYLE="white-space:nowrap">A-1</FONT> </U></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><I>Revise the various references to individuals who &#147;may be deemed&#148; participants to avoid inserting
doubt as to the individuals&#146; status and to be consistent with the definition of participant in instruction 3 to Item 4 of Schedule 14A</I>. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Response to Comment No.</U><U></U><U>&nbsp;2</U>: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">The Company acknowledges the Staff&#146;s comment and advises the Staff that it has revised Annex A of the Proxy Statement to eliminate any
references to the assertion that individuals &#147;may be deemed&#148; participants and revised the disclosure to indicate that such persons are deemed to be participants in the solicitation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">If you should have any questions concerning the enclosed matters, please contact Sean M. Donahue at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">202-538-3557</FONT></FONT> or the undersigned at (617) <FONT STYLE="white-space:nowrap">570-1633.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Sincerely,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Joseph Johnson III, Esq.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:10pt">Joseph Johnson III, Esq.</FONT></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&nbsp;&nbsp;David B. Colleran, Esq., Executive Vice President, General Counsel and Secretary<I>, Anika
Therapeutics, Inc. </I> </P></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Sean M. Donahue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Andrew H. Goodman </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g480900dsp01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g480900dsp01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M;;>6&X6';$^P"T:MIY?\/^ ='Y'0?"]H/@+^W)\5_ ERW]G^$/B[X<N?'>B
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M_P"/@-\$O;X1?#;]/!NBUT1^&/HC-[GR;^WI.87^$RCDN?'0"C))V_\ "&\
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'8I[>5@/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
